Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399110 | 0.99 | ESR1 (0.41) | ESR1ESR2HDAC4CYP2C19APP | |
| SCHEMBL401446 | 0.86 | HDAC4 (0.44) | ESR1ESR2HDAC4CYP2C19APP | |
| SCHEMBL401285 | 0.85 | HDAC4 (0.43) | ESR1ESR2HDAC4CYP2C19CYP2C9 | |
| SCHEMBL4656629 | 0.84 | ESR2 (0.50) | ESR1ESR2CYP2C9CYP3A4 | |
| SCHEMBL402382 | 0.78 | RORC (0.48) | — | |
| SCHEMBL1631912 | 0.71 | HDAC4 (0.41) | HDAC4CYP2C19CYP2C9PDE7AHTT | |
| SCHEMBL1630842 | 0.71 | HDAC4 (0.43) | HDAC4CYP2C19CYP2C9PDE7AHTT | |
| SCHEMBL1256728 | 0.71 | ESR1 (0.66) | ESR1ESR2HDAC4CYP2C19APP | |
| SCHEMBL1629725 | 0.70 | HDAC4 (0.40) | HDAC4CYP2C19CYP2C9PDE7AHTT | |
| SCHEMBL1944655 | 0.70 | MEN1 (0.45) | HDAC4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200994-B1 | CONDENSED COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARM INC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8470872-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470872-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101651-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101651-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101651-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2200994-A1 | CONDENSED COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
| WO-2009055734-A1 | CONDENSED COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088825-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885HDAC4 1962/4885 |
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | ESR1 6/4885ESR2 2/4885HDAC4 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.